| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACAD Stock Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Rewards
Risk Analysis
No risks detected for ACAD from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.14 |
| 52 Week High | US$28.06 |
| 52 Week Low | US$12.24 |
| Beta | 0.67 |
| 1 Month Change | 0.12% |
| 3 Month Change | 12.32% |
| 1 Year Change | -2.83% |
| 3 Year Change | -57.86% |
| 5 Year Change | -57.86% |
| Change since IPO | 140.90% |
Recent News & Updates
FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Acadia Pharmaceuticals (NASDAQ:ACAD) on Monday said the U.S. FDA had accepted its new drug application (NDA) of investigational drug trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. ACAD said the FDA granted the application a priority review and was set to decide on it by March 12, 2023, or the so-called Prescription Drug User Fee Act date. ACAD said the regulatory agency had informed the company that at this time it was not planning to hold an advisory committee meeting to review trofinetide. The NDA was supported by results from a phase 3 study which assessed the efficacy and safety of trofinetide in 187 girls and young women aged 5 through 20 with Rett syndrome. Rett syndrome causes a progressive loss of motor skills and language. It primarily affects females. ACAD stock +3.2% to $17.93 in afternoon trading.
Shareholder Returns
| ACAD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | 1.0% | -3.1% |
| 1Y | -2.8% | -25.8% | -21.5% |
Return vs Industry: ACAD exceeded the US Biotechs industry which returned -24.2% over the past year.
Return vs Market: ACAD exceeded the US Market which returned -20.3% over the past year.
Price Volatility
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 540 | Steve Davis | https://www.acadia-pharm.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It’s pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer’s disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer’s.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD fundamental statistics | |
|---|---|
| Market Cap | US$2.61b |
| Earnings (TTM) | -US$204.62m |
| Revenue (TTM) | US$512.40m |
5.1x
P/S Ratio-12.8x
P/E RatioIs ACAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD income statement (TTM) | |
|---|---|
| Revenue | US$512.40m |
| Cost of Revenue | US$344.87m |
| Gross Profit | US$167.53m |
| Other Expenses | US$372.15m |
| Earnings | -US$204.62m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.26 |
| Gross Margin | 32.70% |
| Net Profit Margin | -39.93% |
| Debt/Equity Ratio | 0% |
How did ACAD perform over the long term?
See historical performance and comparison